Lilly to Build $2.5 Billion Plant As Weight-Loss Demand Booms

Eli Lilly & Co. will build a $2.5 billion manufacturing site in Germany to help expand production capacity for injected medicines like its weight-loss shot Zepbound.

The new plant will help “diversify the growing Lilly presence in Europe,” the company said in a statement. Construction is set to begin next year and Lilly expects it to be operational in 2027. Lilly also said it will invest up to $100 million in Germany’s early-stage biotech ecosystem.

Skyrocketing demand for weight-loss shots from Lilly and rival drugmaker Novo Nordisk A/S has led to struggles to keep up. Lilly’s Mounjaro for diabetes — ...